General Information of Drug (ID: DMHSUQ1)

Drug Name
R-ketoprofen Drug Info
Synonyms
(R)-Ketoprofen; 56105-81-8; (R)-Ketoprophen; UNII-S03709D0TH; (R)-(-)-Ketoprofen; (R)-2-(3-benzoylphenyl)propanoic acid; CHEMBL372052; S03709D0TH; (R)-2-(3-Benzoylphenyl)propionic acid; Benzeneacetic acid,3-benzoyl-a-methyl-, (aR)-; Ketoprofen, (R)-; NCGC00016757-01; CAS-22071-15-4; (2R)-2-(3-benzoylphenyl)propanoic acid; Lopac-K-1751; SCHEMBL195303; ZINC2272; AC1L47D6; CTK5A4646; DTXSID50204652; DKYWVDODHFEZIM-LLVKDONJSA-N; BDBM50169048; AKOS022182275
Cross-matching ID
PubChem CID
180540
CAS Number
CAS 56105-81-8
TTD Drug ID
DMHSUQ1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [1]
Reparixin DMVBA7I Pancreatic islet transplantation failure NE84 Phase 3 [1]
SCH-527123 DMPUAOE Chronic obstructive pulmonary disease CA22 Phase 2 [3]
SX-682 DMHMG6X Melanoma 2C30 Phase 1 [4]
INDOPROFEN DM5QSKN Gout FA25 Withdrawn from market [1]
2-(3-Isopropyl-phenyl)-propionic acid DMUOWNE Discovery agent N.A. Investigative [1]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid DMWIUR0 Discovery agent N.A. Investigative [1]
(R)-2-(4-Isobutyl-phenyl)-propionamide DMBQ0PR Discovery agent N.A. Investigative [1]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide DMWRIQG Discovery agent N.A. Investigative [1]
2-[3-(2-Methyl-butyl)-phenyl]-propionic acid DMKSDT4 Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Interleukin-8 (IL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [2]
ABX-IL8 DMCZFMS Melanoma 2C30 Phase 2 [5]
BMS-986253 DM42B0C Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [6]
MDX-018 DML5FX2 Autoimmune diabetes 5A10 Phase 1 [7]
2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid DM54M6C Discovery agent N.A. Investigative [2]
2-(2-(2-chlorophenylamino)phenyl)acetic acid DMPLV3A Discovery agent N.A. Investigative [2]
2-(2-(2-fluorophenylamino)phenyl)acetic acid DMVQ68F Discovery agent N.A. Investigative [2]
2-(2-(2-chlorophenoxy)phenyl)acetic acid DMBP1TQ Discovery agent N.A. Investigative [2]
2-(2-(2-fluorophenoxy)phenyl)acetic acid DMDSUR2 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 9 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [1]
Clotrimazole DMMFCIH Cutaneous candidiasis 1F23.14 Approved [8]
Reparixin DMVBA7I Pancreatic islet transplantation failure NE84 Phase 3 [1]
SCH-527123 DMPUAOE Chronic obstructive pulmonary disease CA22 Phase 2 [9]
SB-265610 DM8TKG5 Asthma CA23 Phase 2 [10]
AZD-5069 DM3JSFK Asthma CA23 Phase 2 [11]
PS-938285 DMHZIFJ Chronic obstructive pulmonary disease CA22 Phase 2 [12]
GSK1325756 DMA6RBF Chronic obstructive pulmonary disease CA22 Phase 2 [13]
SB-656933 DMCY785 Chronic obstructive pulmonary disease CA22 Phase 2 [14]
RIST4721 DMA3DKO Hidradenitis suppurativa ED92.0 Phase 2 [15]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [16]
Naproxen DMZ5RGV Bursitis Approved [17]
Mesalazine DMOL5IU Diverticulitis Approved [18]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [19]
Bromfenac DMKB79O Pain MG30-MG3Z Approved [20]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [21]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [22]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [21]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [23]
Gamma-Homolinolenic acid DMSXKYG Malnutrition 5B50-5B71 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [25]
Naproxen DMZ5RGV Bursitis Approved [17]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [26]
Indomethacin DMSC4A7 Bursitis Approved [21]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [27]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [28]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [29]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [30]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [19]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 1 (CXCR1) TTMWT8Z CXCR1_HUMAN Inhibitor [1]
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Inhibitor [1]
Interleukin-8 (IL8) TTCTE1G IL8_HUMAN Inhibitor [2]
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [1]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [1]

References

1 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
2 Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
5 Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34.
6 Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.
7 Company report (Genmab)
8 Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
9 CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
10 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
11 Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
12 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
13 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
14 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
15 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.
16 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
17 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
20 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
22 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
23 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
24 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
25 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
26 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
27 Pfizer. Product Development Pipeline. March 31 2009.
28 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
29 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
30 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.